PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-7.99%
Negative revenue growth while AVGO stands at 0.59%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-8.87%
Negative gross profit growth while AVGO is at 0.51%. Joel Greenblatt would examine cost competitiveness or demand decline.
-18.98%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-18.98%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-12.32%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-9.09%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-9.26%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
-3.28%
Share reduction while AVGO is at 0.26%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-3.79%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
-0.35%
Dividend reduction while AVGO stands at 0.14%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
-54.95%
Negative OCF growth while AVGO is at 7.23%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-66.02%
Negative FCF growth while AVGO is at 6.62%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
75.89%
10Y revenue/share CAGR under 50% of AVGO's 409.54%. Michael Burry would suspect a lasting competitive disadvantage.
88.01%
5Y revenue/share CAGR at 50-75% of AVGO's 122.61%. Martin Whitman would worry about a lagging mid-term growth trajectory.
41.12%
3Y revenue/share CAGR at 50-75% of AVGO's 60.90%. Martin Whitman would question if the firm lags behind competitor innovations.
1774.64%
10Y OCF/share CAGR above 1.5x AVGO's 441.92%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
311.93%
5Y OCF/share CAGR above 1.5x AVGO's 73.80%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
57.10%
3Y OCF/share CAGR above 1.5x AVGO's 34.25%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
6975.22%
Net income/share CAGR above 1.5x AVGO's 691.11% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
612.67%
5Y net income/share CAGR similar to AVGO's 651.30%. Walter Schloss might see both on parallel mid-term trajectories.
106.47%
3Y net income/share CAGR above 1.5x AVGO's 66.58%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
93.88%
Below 50% of AVGO's 839.21%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
15.72%
Below 50% of AVGO's 147.32%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
6.14%
Below 50% of AVGO's 188.08%. Michael Burry suspects a serious short-term disadvantage in building book value.
373.82%
Below 50% of AVGO's 1441.93%. Michael Burry might see weaker long-term distribution growth, raising questions about the firm's capital allocation.
352.76%
5Y dividend/share CAGR above 1.5x AVGO's 71.80%. David Dodd checks if the firm's mid-term cash flows justify a faster dividend growth rate.
296.48%
3Y dividend/share CAGR above 1.5x AVGO's 38.29%. David Dodd sees a superior short-term capital return strategy if supported by stable earnings.
-4.19%
Firm’s AR is declining while AVGO shows 14.59%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
11.28%
Inventory growth well above AVGO's 5.71%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
-2.60%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
2.17%
Positive BV/share change while AVGO is negative. John Neff sees a clear edge over a competitor losing equity.
No Data
No Data available this quarter, please select a different quarter.
0.98%
R&D dropping or stable vs. AVGO's 19.53%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
3.08%
SG&A declining or stable vs. AVGO's 14.12%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.